New cell therapy shows promise for hard-to-treat blood cancers in japanese patients

NCT ID NCT06253663

Ongoing Disease control Sponsor: Kite, A Gilead Company Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 26 times

Summary

This study tests a treatment called KTE-X19 in 25 Japanese adults whose mantle cell lymphoma or B-cell acute lymphoblastic leukemia has come back or stopped responding to other treatments. KTE-X19 is a type of immunotherapy that uses a patient's own immune cells to fight cancer. The main goal is to see how many patients achieve remission or a significant reduction in cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Chiba University Hospital

Chiba, 260-8677, Japan
Hokkaido University Hospital

Hokkaido, 060-8648,, Japan
Juntendo University Hospital

Tokyo, 113-8431, Japan
Kyoto University Hospital

Kyoto, 606-8507, Japan
Kyushu University Hospital

Fukuoka, 812-8582, Japan
National Cancer Center Hospital

Tokyo, 104-0045, Japan
Okayama University Hospital

Okayama, 700-8558, Japan
Tohoku University Hospital

Miyagi, 980-8574, Japan
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital

Tokyo, 113-8677, Japan

Conditions

Explore the condition pages connected to this study.

RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA